StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.32−0.08 (-1.48%)

Close on Nov 18, 2026Market cap $407.08MP/E –Yield –

Candel Therapeutics cash

Cash and short-term investments held at the end of each period.

Candel Therapeutics's cash was $201.57M at Jun 30, 2026. For fiscal 2025 it was $119.73M, up 16.3% from the year before. The highest annual figure on record is $119.73M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$119.73M+16.3%
FY2024Dec 31, 2024$102.92M+188.5%
FY2023Dec 31, 2023$35.68M-49.3%
FY2022Dec 31, 2022$70.32M-15.3%
FY2021Dec 31, 2021$83.07M+135.2%
FY2020Dec 31, 2020$35.32M+548.7%
FY2019Dec 31, 2019$5.45M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$201.57M+99.7%
Q1 FY2026Mar 31, 2026$194.83M+110.8%
Q4 FY2025Dec 31, 2025$119.73M+16.3%
Q3 FY2025Sep 30, 2025$86.96M+416.9%
Q2 FY2025Jun 30, 2025$100.95M+364.8%
Q1 FY2025Mar 31, 2025$92.43M+255.8%
Q4 FY2024Dec 31, 2024$102.92M+188.5%
Q3 FY2024Sep 30, 2024$16.82M-61.1%
Q2 FY2024Jun 30, 2024$21.72M-58.4%
Q1 FY2024Mar 31, 2024$25.98M-56.4%
Q4 FY2023Dec 31, 2023$35.68M-49.3%
Q3 FY2023Sep 30, 2023$43.25M-44.2%
Q2 FY2023Jun 30, 2023$52.16M-40.1%
Q1 FY2023Mar 31, 2023$59.52M-37.2%
Q4 FY2022Dec 31, 2022$70.32M-15.3%
Q3 FY2022Sep 30, 2022$77.45M-12.8%
Q2 FY2022Jun 30, 2022$87.05M+251.9%
Q1 FY2022Mar 31, 2022$94.76M+220.4%
Q4 FY2021Dec 31, 2021$83.07M+135.2%
Q3 FY2021Sep 30, 2021$88.81M+379.4%
Q2 FY2021Jun 30, 2021$24.74M+19.2%
Q1 FY2021Mar 31, 2021$29.58M+443.2%
Q4 FY2020Dec 31, 2020$35.32M–
Q3 FY2020Sep 30, 2020$18.52M–
Q2 FY2020Jun 30, 2020$20.76M–
Q4 FY2019Dec 31, 2019$5.45M–

More Candel Therapeutics figures

See a number that looks wrong?